Acorda Therapeutics Inc (ACORQ)
0.44
-0.21
(-32.31%)
USD |
OTCM |
May 10, 16:00
Acorda Therapeutics Free Cash Flow: -14.25M for Dec. 31, 2023
Free Cash Flow Chart
Historical Free Cash Flow Data
| Date | Value |
|---|---|
| December 31, 2023 | -14.25M |
| September 30, 2023 | -1.997M |
| June 30, 2023 | -11.37M |
| March 31, 2023 | -14.40M |
| December 31, 2022 | -21.06M |
| September 30, 2022 | -27.01M |
| June 30, 2022 | -34.03M |
| March 31, 2022 | -28.27M |
| December 31, 2021 | -41.54M |
| September 30, 2021 | -43.65M |
| June 30, 2021 | -37.39M |
| March 31, 2021 | -51.31M |
| December 31, 2020 | -65.40M |
| September 30, 2020 | -91.97M |
| June 30, 2020 | -132.71M |
| March 31, 2020 | -157.47M |
| December 31, 2019 | -218.59M |
| September 30, 2019 | -216.48M |
| June 30, 2019 | -106.78M |
| March 31, 2019 | -9.162M |
| December 31, 2018 | 116.88M |
| September 30, 2018 | 197.03M |
| June 30, 2018 | 180.88M |
| March 31, 2018 | 137.92M |
| December 31, 2017 | 82.76M |
| Date | Value |
|---|---|
| September 30, 2017 | 52.40M |
| June 30, 2017 | 12.84M |
| March 31, 2017 | -280.41M |
| December 31, 2016 | -243.89M |
| September 30, 2016 | -249.28M |
| June 30, 2016 | -238.80M |
| March 31, 2016 | 48.64M |
| December 31, 2015 | 31.42M |
| September 30, 2015 | -456.46M |
| June 30, 2015 | -440.25M |
| March 31, 2015 | -423.42M |
| December 31, 2014 | -409.28M |
| September 30, 2014 | 75.73M |
| June 30, 2014 | 48.70M |
| March 31, 2014 | 36.14M |
| December 31, 2013 | 24.62M |
| September 30, 2013 | 20.61M |
| June 30, 2013 | 26.80M |
| March 31, 2013 | 29.93M |
| December 31, 2012 | 38.54M |
| September 30, 2012 | 53.62M |
| June 30, 2012 | 79.64M |
| March 31, 2012 | 72.83M |
| December 31, 2011 | 60.55M |
| September 30, 2011 | 32.52M |
Free Cash Flow Range, Past 5 Years
-218.59M
Minimum
Dec 2019
-1.997M
Maximum
Sep 2023
-69.25M
Average
-41.54M
Median
Dec 2021
Free Cash Flow Benchmarks
| BioSig Technologies Inc | -17.50M |
| Verve Therapeutics Inc | -149.88M |
| Spectral AI Inc | -12.03M |
| AIM ImmunoTech Inc | -21.85M |
| Protalix BioTherapeutics Inc | -2.467M |
Free Cash Flow Related Metrics
| Cash from Operations (Quarterly) | -3.018M |
| Cash from Investing (Quarterly) | -0.044M |
| Free Cash Flow Per Share (Quarterly) | -2.465 |
| Free Cash Flow to Equity (Quarterly) | -8.162M |
| Free Cash Flow to Firm (Quarterly) | 3.732M |
| Free Cash Flow Yield | -2.62K% |